Honestly, looking at the NNOX stock price right now feels a bit like watching a high-stakes poker game where one player is shouting "All in!" while the rest of the table is busy checking their phones. As of mid-January 2026, the stock is hovering around the $3.00 to $3.15 mark. It’s a weird spot to be. On one hand, you have Nano-X Imaging management basically promising the moon—specifically a $35 million revenue target for 2026. On the other hand, the market is treating those claims with a massive side-eye, keeping the price pinned near its 52-week lows.
If you’ve been following this company for a while, you know the drill. It’s a cycle of grand technological promises followed by the cold, hard reality of medical device regulation and slow-burn commercialization.
The $35 Million Elephant in the Room
Let's talk about that revenue guidance. In late 2025, CEO Erez Meltzer dropped a bombshell: the company expects to hit $35 million in revenue for 2026. To put that in perspective, their Q3 2025 revenue was a modest $3.4 million. They are essentially betting they can more than double their annual run rate in a single year.
Where is that money supposed to come from?
It’s not just about selling boxes anymore. The NNOX stock price is increasingly tied to a three-headed monster of revenue streams:
🔗 Read more: Is Big Lots Going Out of Business in 2024? What Most People Get Wrong
- Teleradiology: This is currently their bread and butter, bringing in over $3 million a quarter. It’s steady, but it’s not "explosive."
- Nanox.ARC Hardware: The actual digital X-ray "Star Trek" tech. This has been the laggard. In Q3 2025, system sales and deployments only chipped in about $175,000.
- AI Solutions: Through Nanox.AI and the recent Vaso Healthcare IT acquisition, they’re trying to monetize the interpretation of scans.
The skepticism from Wall Street—and why the price hasn't rocketed yet—is simple. Moving from $175,000 in hardware revenue to the millions needed to hit that $35 million target requires a massive "inflection point" in deployments.
FDA Clearances and the 2026 Rollout
One thing the bears often overlook is that Nano-X isn't just vaporware anymore. They actually have the clearances. In April 2025, the FDA gave the green light to the Nanox.ARC X, their multi-source digital tomosynthesis system. This was huge. It’s cleared for musculoskeletal, pulmonary, and intra-abdominal indications.
Basically, it’s a machine that aims to provide CT-like 3D images at a fraction of the cost and radiation.
📖 Related: Who is Actually Running BP? The People on the BP Board of Directors Right Now
Recent Wins You Might Have Missed:
- Southeast Europe Expansion: Just days ago, in January 2026, they inked a deal with Adriamed to distribute the ARC system across Serbia, Montenegro, and Bosnia and Herzegovina.
- The French Connection: They’ve partnered with Althea France to push into one of Europe’s biggest medical markets.
- The 3DR Labs Deal: This is probably the most underrated catalyst. 3DR Labs is a massive US reseller that services over 1,800 hospitals. If they can start moving Nanox.AI software through this channel, the high-margin "software-as-a-service" revenue could finally start showing up on the balance sheet.
Why the Stock is Flatlining Despite "Good" News
You’d think a partnership with 1,800 hospitals would send the NNOX stock price to the moon. It hasn't. Why?
Cash burn. In late 2025, the company's cash reserves sat at roughly $55.5 million. That sounds like a lot until you realize they had an operating cash burn of over $30 million recently. They even had to do a $15 million direct offering in November 2025 just to keep the lights on and the assembly lines moving. Investors are terrified of dilution. Every time the stock starts to rally, the threat of another share offering acts like a wet blanket.
Also, let's be real: the GAAP gross loss is still a thing. They are spending more to build and deploy these systems than they are currently making from them. It’s a classic "J-curve" growth story, but the market in 2026 is much less patient with unprofitable tech than it was in 2021.
The AI Wildcard: NVIDIA and the "Last Mile"
There is a lot of chatter about NNOX being an "AI play." While they aren't directly building chips like NVIDIA, they are deeply embedded in the ecosystem. NVIDIA's MONAI framework is becoming the standard for medical AI, and companies like Nano-X are the ones providing the "clinical tools" that actually use those models.
The goal for Nano-X in 2026 is to bridge the gap between a cool algorithm and a tool a radiologist actually uses to save a life. Their HealthCCSng (cardiac), HealthOST (bone), and HealthFLD (liver) AI tools are already FDA-cleared. If they can prove that these tools save hospitals money by catching chronic diseases early, the valuation of NNOX could shift from "struggling hardware maker" to "essential AI infrastructure."
💡 You might also like: The Truth About the Dollar to Ruble Exchange Rate and Why It Keeps Moving
What to Watch Next
If you’re looking for a move in the NNOX stock price, mark your calendar for late March 2026. That’s when the Q4 2025 earnings report should drop.
Don't look at the bottom line—it’ll probably be a loss. Look at the unit count. Management set a goal to have over 100 units deployed globally by the end of 2025. If they missed that number, expect the stock to test that $2.70 floor. If they beat it and show a significant jump in hardware-related revenue, we might finally see that "inflection point" the bulls have been dreaming about.
Actionable Insights for Investors:
- Monitor the Cash Runway: Keep a close eye on the quarterly burn rate. If cash dips below $30 million without a massive spike in revenue, another dilution event is almost certain.
- Follow the "Vaso" Integration: The Vaso Healthcare IT acquisition was meant to accelerate US deployment. Check for updates on how many US sites are actually "going live" with Nanox.ARC.
- Watch the $2.75 Level: Historically, $2.70 - $2.80 has been a "line in the sand" for buyers. A break below this could signal a long-term breakdown, while a bounce here keeps the recovery narrative alive.
- Analyze the AI Peer Group: Compare NNOX's price action to other small-cap AI medical stocks like Butterfly Network or GE HealthCare’s digital segments. Sometimes the move is industry-wide rather than company-specific.
The path to $35 million is narrow and full of regulatory hurdles. But if Nano-X can even get close to that number, the current $3 price tag will look like a historical anomaly. Just remember, in the world of med-tech, "revolutionary" usually takes twice as long and costs three times as much as the slide deck says.
To get a better sense of where the company stands, your next move should be digging into the SEC Form 6-K filings from the November 2025 direct offering to see the exact warrants and price protections given to institutional investors, as these often act as a ceiling for the stock price in the short term.